TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS
6.1. Overview
6.2. Bisphosphonates
6.3. Selective Estrogen Receptor Modulators (SERMs)
6.4. Anabolic Class
6.5. RANK Ligand Inhibitors
6.6. Calcium Metabolism Modifiers
6.7. Others
7. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Oral
7.3. Intravenous Route
7.4. Subcutaneous
8. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Postmenopausal Osteoporosis Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Postmenopausal Osteoporosis Market,
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. Pfizer Inc.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Amgen
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. F. Hoffmann-La Roche Ltd
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Novartis AG
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Chugai Pharma China Co., Ltd.
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Teva Pharmaceutical Industries Ltd.
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Fresenius Kabi AG
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Hikma Pharmaceuticals PLC
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. GlaxoSmithKline plc
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Sun Pharmaceutical Industries Ltd
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Paras Biopharmaceuticals Finland Oy
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Ligand Pharmaceuticals Incorporated
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Products Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Eli Lilly and Company
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Products Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 US: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 10 US: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 11 US: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 12 CANADA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 13 CANADA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 ITALY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 11 ITALY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 16 UK: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 17 UK: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 18 UK: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 28 CHINA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 29 CHINA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 31 INDIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 32 INDIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET
FIGURE 4 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY DRUG CLASS, 2023
FIGURE 5 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 6 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 7 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: POSTMENOPAUSAL OSTEOPOROSIS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 PFIZER INC.: SWOT ANALYSIS
FIGURE 15 AMGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 AMGEN: SWOT ANALYSIS
FIGURE 17 F. HOFFMANN-LA ROCHE LTD : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 F. HOFFMANN-LA ROCHE LTD : SWOT ANALYSIS
FIGURE 19 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 NOVARTIS AG: SWOT ANALYSIS
FIGURE 21 CHUGAI PHARMA CHINA CO., LTD..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 CHUGAI PHARMA CHINA CO., LTD..: SWOT ANALYSIS
FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 25 FRESENIUS KABI AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 FRESENIUS KABI AG: SWOT ANALYSIS
FIGURE 27 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS
FIGURE 29 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 33 PARAS BIOPHARMACEUTICALS FINLAND OY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 PARAS BIOPHARMACEUTICALS FINLAND OY: SWOT ANALYSIS
FIGURE 35 LIGAND PHARMACEUTICALS INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 LIGAND PHARMACEUTICALS INCORPORATED: SWOT ANALYSIS
FIGURE 37 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 ELI LILLY AND COMPANY: SWOT ANALYSIS
